Trading Summary - January 16. Another satisfactory

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
208
Trading Summary - January 16.

Another satisfactory status quo day for $DIGX.

A bid of 119M at .0003 was maintained for the majority of the day - may have been higher but I was busy with multiple other movers from my 3 x watch lists. The ask was the same at 31M of which 9M appear to be put up as a day trade.

This bid continued to send a clear message to anyone that wanted to sell that the were eager buyers for $35,700 worth of $DIGX to build up an inventory of shares to trade from year bottom prices on all the runs coming in 2018. Those funds are sufficient to clear the .0004s and .0005s when applied to the ask at some point going forward.

The bashers didn't even bother attempting to paint down today although they continue to post non-credible nonsense on iHub.

This top profit earner of 2017 - from regular repeat runs as shown in post # 2189 - is now set up for the same in 2018.

As always, anything could happen at anytime. So stay sharp if you don't already have all the shares you need to make your profit expectations up to Q4 in March 2018 and thereafter throughout 2018. Prior warning and / or scanner alerts of any significant buys starting a run up will not be given on iHub but they will be alerted here immediately. 2 of the 4 recognized repeat whale traders in $DIGX are back posting on iHub already.

Content below the line unchanged from last update - relevant to those that are new here.

Be aware that, in 2017, PRs came out in both Jan and Feb. Likely items to be PR'ed are:

- Shares retired in 2017 (425M known to followers here but not PR'ed yet).

- Excellent 3Q results.

- Provisional 4Q results - including anticipated dramatic increase over 3Q due to additional services now being provided in the chiropractic offices - in Strategic Growth Plan - equipment already acquired at start of Q4).

- Further acquisition plans for brand growth.

237M bought at .0003 since August 23 - the majority by longs building an inventory of shares to be traded on the several runs that are likely to come in 2018.

All followers of $DIGX here have had no excuse for not being set up for 2018 already. There has been ample opportunity to load a combination of .0003s and .0004s for 20 weeks - with .0004s being the only realistic option left now for any significant amount (but most likely not for much longer).

The .0004s could easily disappear in seconds / minutes - and the .0005s shortly thereafter - setting off a run towards .0010 - just like happened Jan 17-19, 2017 before the first PR.

The PR associated with the 2017 Q3 - that was filed on November 16 - has not been issued yet. The PR associated with 2016 Q3 came out on December 12, 2016 - see here:

http://www.otcmarkets.com/stock/DIGX/news/DIG...08&b=y

Until the PR comes out highlighting the excellent results - and hopefully also updating future brand expansion plans - only those who were looking for the Q3 - who mostly already have their shares - have seen it.

http://www.otcmarkets.com/stock/DIGX/news/DIG...08&b=y

In due course, the Q4 results will speak for themselves and - when PR'ed to the wider investing community - we should see serious additional new interest due to the low O/S and relatively high positive revenue for a stock in this price range - just as happened for the 2016 Q4 and the 2017 Q1 and Q2.

As previously stated, the large additional share retirement of 275M shares since Jul 31 - on top of the 150M retired Dec 2016 > May 2017 making 425M total - has not been PR'ed yet either.

Excellent update recently on the Verified Company Profile share structure at otcmarkets.com from the Transfer Agent (see new sticky #2148) - this has not been PR'ed yet to the wider investing community:

A/S and O/S confirmed unchanged as at Dec 31, 2017.

Float same as for all the runs this year - 50M reduction since Dec 2016.

Another 275M shares retired between Jul 31 and Oct 31 (as promised).

That takes total retired to 425M since May 31 - a significant reduction on such a small O/S and A/S for a stock in this price range.

The long-term whales who trade $DIGX will continue to buy shares at any price that makes sense to them to use on multiple runs throughout 2018. It is already known from posted comments and observation that at least 4 of the main whales bought shares - on the bid and on the ask - from the impatient at the end of 2017.

As predicted, at least 4 x whales who trade $DIGX continuously throughout each year were happy to take around 100M at .0003 when a few impatient people decided to trade for a loss at .0003 on December 14.

The big boys in DIGX now probably already have an inventory of 50M>200M each for trading throughout 2018.

Any shares bought at .0004 will be worth an easy 150%+ profit on any of numerous runs likely to happen through to Q4. Shares bought at .0005 should easily return 100%+ at some point in 2018.

In my experience, 70M>100M is the optimum amount to take best advantage of each run (and starting the year with an inventory of around 250M) whilst keeping the 25M cheapest batches for any bigger runs that might occur in the .0020 > .0050 range at some future point. My cheapest 25M retained for that eventuality will not require any shares bought above .0003 now so all others will be tradeable going forward.

As expected, the status quo has been pretty much maintained throughout Q4 2017 with it making little difference to long-term traders whether shares are picked up at .0003/4/5/6 - they will see a profit on all of them by Q4 in March 2018 and on any runs beforehand.

We can now look forward to additional updates on both the possible merger discussed and the implementation of the additional services being offered in the chiropractic chain offices - per the Strategic Growth Plan that was also announced earlier - over the coming days, weeks and months.

As predicted in October 2017, $DIGX was not allowed to go to the 2016 year-end low of .0002 ask at end-2017.

In my opinion, nobody has bought $DIGX in 2017 at a price that it isn't likely to exceed in 2018.

Ludicrous claims by the notorious bashers currently on iHub - "RFB", "munimi", "Crown Capital", "Homebrew" and "surfkast" - are clearly seen as such by all serious traders and now even by most iHubbers.

Debunking nonsense posted by morons on iHub, there is absolutely no need or intention to do a reverse split. The share structure is exceptionally thin - with no dilution - and the company has been buying back shares. OTC market specialists who trade $DIGX continuously would not have loaded 50M>250M shares at end-2017 prices to trade over the next 12 months if there was even the remote possibility of a reverse split.

There have never been any promotion campaigns on $DIGX in the modern era on the current business model - since the acquisition of Expressions Chiropractic & Rehab in January 2016 and I don't think there will be any. The PRs alone + OTC market off-the-bottom specialists spotting the loading on scanners, keeping accurate records and networking with other traders has proved sufficient to generate multiple runs in 2017 and should do the same in future throughout 2018.

Regardless of whether iHub posters lose interest over the coming days and weeks, detailed coverage will continue here as $DIGX remains one of my top picks for repeat profits for those that are patient and trade it to best effect (keep all cheapest batches of shares - create an inventory of shares at higher prices to trade on every run - big or small). It was the top earner in 2017 and remains the top pick for repeat runs in 2018.

In addition, money is not considered "dead" by the most successful traders in the OTC market when they know it will provide a significant return further down the line because they are in a position to understand and influence - through keen observation and record keeping - what volume of shares is likely to be made available for purchase at any particular level.












American EcoFuels Inc (AEFI) Stock Research Links

AEFI Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles